<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6514695\results\search\drugs\results.xml">
  <result pre="silybin A and silybin B (1:1) is also known as" exact="silibinin" post="(C25H22O10, PubChem CID: 31553; Figure 1), which makes up"/>
  <result pre="et al. in 2013 showed that the major bioactive component" exact="silibinin" post="exerts antiviral effect against HCV by blocking clathrin-mediated endocytosis"/>
  <result pre="blocking clathrin-mediated endocytosis [12]. Another study in 2013 indicated that" exact="silibinin" post="impedes HCV infection by targeting the HCV NS4B protein"/>
  <result pre="morphogenesis of the viral replication sites. More recently, we developed" exact="silibinin" post="nanoparticles (SB-NPs) and showed that both the SB-NPs and"/>
  <result pre="(SB-NPs) and showed that both the SB-NPs and the conventional" exact="silibinin" post="inhibited HCV infection by blocking viral cell-to-cell spread [15]."/>
  <result pre="that the oral and intravenous (i.e., Legalon® SIL) formulations of" exact="silibinin" post="exert different effects on HCV life cycle, inflammation, and"/>
  <result pre="identified nine phytochemicals possessing potential inhibitory effects against NS4B, including" exact="silibinin" post="and other compounds from the plant S. marianum [18]."/>
  <result pre="from the plant S. marianum [18]. This result suggests that" exact="silibinin" post="could potentially inhibit DENV viral replication. Given that molecular"/>
  <result pre="this important pathogen is highly envisaged. Gazák et al. developed" exact="silibinin" post="derivatives that were conjugated with long-chain fatty acids and"/>
  <result pre="and demonstrated their superior anti-influenza virus activity compared to conventional" exact="silibinin" post="in plaque reduction assay [21]. Later, using cytopathic effect"/>
  <result pre="Interestingly, this finding is compatible with the accumulation of free" exact="silibinin" post="in lung after oral administration that others and we"/>
  <result pre="its ability to block HIV entry. Thus, it appears that" exact="silibinin" post="could simultaneously block HIV entry and T-cell activation. Combined"/>
  <result pre="needed. Recently, Umetsu et al. demonstrated that similar to HCV," exact="silibinin" post="inhibited HBV entry into the permissive HepG2-NTCP-C4 and PXB"/>
  <result pre="interaction, replication or release [31]. More importantly, the combination of" exact="silibinin" post="and Entecavir, a known nucleoside reverse transcriptase inhibitor, reduced"/>
  <result pre="studies have evaluated the effect of silymarin or its component" exact="silibinin" post="in patients with chronic hepatitis C. Oral administration of"/>
  <result pre="12-month silybin-vitamin E-phospholipid complex pills supplemented to pegylated-interferon (Peg-IFN) +" exact="ribavirin" post="(RBV) treatment achieved lower viral load compared to those"/>
  <result pre="difference between these results may imply the importance of improving" exact="silibinin" post="or silybin’s solubility to enhance its effect in clinical"/>
  <result pre="the use of other solvents such as ethanol, glyceryl monooleate," exact="polysorbate" post="20, and transcutol may help increase its solubility ranging"/>
  <result pre="in addressing the solubility and bioavailability issue of the standardized" exact="silibinin" post="(silybin isomers). Specifically, silibinin-loaded nanoparticles (SB-NP) with diameters &amp;lt;200"/>
  <result pre="carrier polyvinylpyrrolidone (PVP), which resulted in the transition of the" exact="silibinin" post="crystalline structure into an amorphous state in the SB-NP"/>
  <result pre="SB-NP and demonstrated a significantly enhanced solubility [15]. Interestingly, free" exact="silibinin" post="was efficiently released from the nanoformulation at pH 7.4"/>
  <result pre="superior biodistribution to the liver was observed compared to non-modified" exact="silibinin" post="following oral administration in rats [15]. The orally applicable"/>
  <result pre="in Huh-7 Cells Harboring Subgenomic RepliconsJ. Virol.2003775487549210.1128/JVI.77.9.5487-5492.200312692249 15.LiuC.H.LinC.C.HsuW.C.ChungC.Y.LinC.C.JasseyA.ChangS.P.TaiC.J.TaiC.J.ShieldsJ.et al.Highly bioavailable" exact="silibinin" post="nanoparticles inhibit HCV infectionGut2017661853186110.1136/gutjnl-2016-31201927436270 16.DebRoyS.HiragaN.ImamuraM.HayesC.N.AkamatsuS.CaniniL.PerelsonA.S.PohlR.T.PersianiS.UprichardS.L.Hepatitis C virus dynamics and"/>
  <result pre="expression in uPA-SCID chimeric mice with humanized livers during intravenous" exact="silibinin" post="monotherapyJ. Viral Hepat.20162370871710.1111/jvh.1255127272497 17.WagonerJ.MorishimaC.GrafT.N.OberliesN.H.TeissierE.PécheurE.-I.TavisJ.E.PolyakS.J.Differential In Vitro Effects of Intravenous"/>
  <result pre="Among Korean American ParentsJ. Immigr. Minor. Heal.20172094395010.1007/s10903-017-0609-128639095 31.UmetsuT.InoueJ.KogureT.KakazuE.NinomiyaM.IwataT.TakaiS.NakamuraT.SanoA.ShimosegawaT.Inhibitory effect of" exact="silibinin" post="on hepatitis B virus entryBiochem. Biophys. Rep.201814202510.1016/j.bbrep.2018.03.00329872730 32.WuY.-F.FuS.-L.KaoC.-H.YangC.-W.LinC.-H.HsuM.-T.TsaiT.-F.Chemopreventive Effect"/>
  <result pre="37.MalaguarneraG.BertinoG.ChisariG.MottaM.VecchioM.VacanteM.CaraciF.GrecoC.DragoF.NunnariG.et al.Silybin supplementation during HCV therapy with pegylated interferon-α plus" exact="ribavirin" post="reduces depression and anxiety and increases work abilityBMC Psychiatry20161639810.1186/s12888-016-1115-z27842532"/>
  <result pre="Hepatitis C Viremia Induced by Intravenous Silibinin Plus RibavirinGastroenterology200913739039110.1053/j.gastro.2009.02.08719486953 42.RutterK.ScherzerT.-M.BeinhardtS.KerschnerH.StättermayerA.F.HoferH.Popow-KrauppT.Steindl-MundaP.FerenciP.Intravenous" exact="silibinin" post="as ‘rescue treatment’ for on-treatment non-responders to pegylated interferon/ribavirin"/>
  <result pre="on-treatment non-responders to pegylated interferon/ribavirin combination therapyAntivir. Ther.2011161327133310.3851/IMP194222155914 43.BiermerM.SchlosserB.FülöpB.van BömmelF.BrodzinskiA.HeyneR.KellerK.SarrazinC.BergT.High-dose" exact="silibinin" post="rescue treatment for HCV-infected patients showing suboptimal virologic response"/>
  <result pre="prevention of hepatitis C virus (HCV) liver graft reinfection by" exact="silibinin" post="mono-therapyJ. Hepatol.20105295195210.1016/j.jhep.2010.02.00220413176 47.BeinhardtS.Rasoul-RockenschaubS.ScherzerT.M.FerenciP.Silibinin monotherapy prevents graft infection after orthotopic"/>
  <result pre="CJ. Hepatol.20115459159210.1016/j.jhep.2010.09.00921106270 48.EurichD.BahraM.BergT.Boas-KnoopS.BiermerM.NeuhausR.NeuhausP.NeumannU.Treatment of hepatitis C-virus-reinfection after liver transplant with" exact="silibinin" post="in nonresponders to pegylated interferon-based therapyExp. Clin. Transplant.201191621605016 49.AghemoA.BhooriS.De"/>
  <result pre="Graft ReinfectionHepat. Mon.20121241141410.5812/hepatmon.613522879832 50.KnapsteinJ.WörnsA.M.GalleP.R.ZimmermannT.Combination therapy with silibinin, pegylated interferon and" exact="ribavirin" post="in a patient with hepatitis C virus genotype 3"/>
  <result pre="after liver transplantation: A case reportJ. Med. Case Rep.2014825710.1186/1752-1947-8-25725047566 51.MariñoZ.CrespoG.D’AmatoM.BrambillaN.GiacovelliG.RovatiL.CostaJ.NavasaM.FornsX.Intravenous" exact="silibinin" post="monotherapy shows significant antiviral activity in HCV-infected patients in"/>
  <result pre="peri-transplantation periodJ. Hepatol.20135841542010.1016/j.jhep.2012.09.03423063567 52.RendinaM.D’AmatoM.CastellanetaA.CastellanetaN.M.BrambillaN.GiacovelliG.RovatiL.RizziS.F.ZappimbulsoM.BringiottiR.S.et al.Antiviral activity and safety profile of" exact="silibinin" post="in HCV patients with advanced fibrosis after liver transplantation:"/>
  <result pre="trialTranspl. Int.20142769670410.1111/tri.1232424673819 53.BárcenaR.MorenoA.Rodriguez-GandiaM.A.AlbillosA.ArocenaC.BlesaC.García-HozF.GrausJ.NuñoJ.López-HervásP.et al.Safety and anti-HCV effect of prolonged intravenous" exact="silibinin" post="in HCV genotype 1 subjects in the immediate liver"/>
  <result pre="56.PayerB.ReibergerT.RutterK.BeinhardtS.StaettermayerA.Peck-RadosavljevicM.FerenciP.Successful HCV eradication and inhibition of HIV replication by intravenous" exact="silibinin" post="in an HIV–HCV coinfected patientJ. Clin. Virol.20104913113310.1016/j.jcv.2010.07.00620709593 57.BraunD.RauchA.DurischN.EberhardN.AnagnostopoulosA.LedergerberB.MetznerK.J.BöniJ.WeberR.FehrJ.Efficacy of"/>
  <result pre="in an HIV–HCV coinfected patientJ. Clin. Virol.20104913113310.1016/j.jcv.2010.07.00620709593 57.BraunD.RauchA.DurischN.EberhardN.AnagnostopoulosA.LedergerberB.MetznerK.J.BöniJ.WeberR.FehrJ.Efficacy of lead-in" exact="silibinin" post="and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected"/>
  <result pre="biopharmaceutical evaluation of silymarin using SMEDDSArch. Pharmacal. Res.200730828910.1007/BF02977782 60.WuJ.-W.LinL.-C.HungS.-C.ChiC.-W.TsaiT.-H.Analysis of" exact="silibinin" post="in rat plasma and bile for hepatobiliary excretion and"/>
  <result pre="of pharmacokineticsJ. Ethnopharmacol.200912118519310.1016/j.jep.2008.10.03619041708 62.WeyhenmeyerR.MascherH.BirkmayerJ.Study on dose-linearity of the pharmacokinetics of" exact="silibinin" post="diastereomers using a new stereospecific assayInt. J. Clin. Pharmacol."/>
  <result pre="silybin glycosidesPhytother. Res.200216Suppl. 1S33S3910.1002/ptr.79611933137 66.MiraL.SilvaM.MansoC.Scavenging of reactive oxygen species by" exact="silibinin" post="dihemisuccinateBiochem. Pharmacol.19944875375910.1016/0006-2952(94)90053-18080448 67.MaheshwariH.AgarwalR.PatilC.KatareO.P.Preparation and pharmacological evaluation of silibinin liposomesArzneimittelforschung20035342042710.1055/s-0031-129713012872613"/>
  <result pre="species by silibinin dihemisuccinateBiochem. Pharmacol.19944875375910.1016/0006-2952(94)90053-18080448 67.MaheshwariH.AgarwalR.PatilC.KatareO.P.Preparation and pharmacological evaluation of" exact="silibinin" post="liposomesArzneimittelforschung20035342042710.1055/s-0031-129713012872613 68.KumarN.RaiA.ReddyN.D.RajP.V.JainP.DeshpandeP.MathewG.KuttyN.G.UdupaN.RaoC.M.Silymarin liposomes improves oral bioavailability of silybin besides"/>
 </snippets>
</snippetsTree>
